Foresite Capital Management III as of Sept. 30, 2017
Portfolio Holdings for Foresite Capital Management III
Foresite Capital Management III holds 20 positions in its portfolio as reported in the September 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Aerie Pharmaceuticals | 26.1 | $95M | 2.0M | 48.60 | |
| Alder Biopharmaceuticals | 9.9 | $36M | 2.9M | 12.25 | |
| Immunomedics | 9.2 | $33M | 2.4M | 13.98 | |
| Blueprint Medicines (BPMC) | 9.0 | $33M | 468k | 69.67 | |
| Achaogen | 8.4 | $31M | 1.9M | 15.95 | |
| Aimmune Therapeutics | 6.2 | $23M | 912k | 24.79 | |
| Wave Life Sciences (WVE) | 5.2 | $19M | 863k | 21.75 | |
| Epizyme | 4.5 | $16M | 850k | 19.05 | |
| Myokardia | 3.5 | $13M | 295k | 42.85 | |
| Acceleron Pharma | 2.9 | $10M | 279k | 37.32 | |
| Ascendis Pharma A S (ASND) | 2.9 | $10M | 285k | 36.25 | |
| Verona Pharma Plc ads (VRNA) | 2.6 | $9.3M | 609k | 15.35 | |
| Aclaris Therapeutics (ACRS) | 1.9 | $6.8M | 263k | 25.81 | |
| Pacific Biosciences of California (PACB) | 1.7 | $6.0M | 1.2M | 5.25 | |
| Cymabay Therapeutics | 1.3 | $4.8M | 600k | 8.06 | |
| Loxo Oncology | 1.3 | $4.6M | 50k | 92.12 | |
| Madrigal Pharmaceuticals (MDGL) | 1.2 | $4.5M | 100k | 44.98 | |
| Argenx Se (ARGX) | 1.1 | $4.0M | 177k | 22.61 | |
| Tocagen | 1.0 | $3.7M | 293k | 12.46 | |
| Dermira | 0.3 | $1.2M | 43k | 27.00 |
